The Internet is poised to play a growing role in recruiting for Alzheimer’s clinical trials.
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
With several microRNAs being overly active in ALS, an antisense therapy to one slows the disease in mice, apparently by reducing neuroinflammation.
New strategies may help find and retain participants for Alzheimer’s trials.
Changing ApoE levels in midlife influences Aβ pathology in mice, supporting an ApoE-oriented therapeutic strategy in Alzheimer’s disease.
Researchers propose four stages of TDP-43 pathology based on the spread of the protein through the brain.
Meet ADCS-PACC, C3: Composites that measure subtle changes in cognition appear reliable, clearing the way for their use in clinical trials of people with presymptomatic AD.
The FDA has approved a second tracer, flutemetamol, for PET imaging of amyloid plaques in the brain.
Known for his contributions to the fundamental understanding of the tau protein, Skip Binder leaves his mark on the Alzheimer's field.
Researchers find an actin-binding protein in stress granules, linking the cytoskeleton and RNA sequestration in the pathology of amyotrophic lateral sclerosis.
A mouse with TDP-43 proteinopathy looks to be an unlikely model for testing amyotrophic lateral sclerosis drugs.
A proof-of-concept study suggests that amyloid imaging will offer insights into traumatic brain injury.
The latest news on C9ORF72 includes a genetic modifier, various animal models, and a potential treatment to untangle stable, guanine-based structures formed by expanded repeats.
New regulatory initiatives will soon make clinical trial data more publicly available than ever, but industry and other groups warn that the move could endanger patient privacy and lead to misuse of data.
Stacked together, amyloid subunits absorb more light than they do as monomers. Are there implications for fibril detection?